Mechanism of Action
FXa. It does not require antithrombin III for antithrombotic activity. Apixaban inhibits free and clot-bound FXa, and prothrombinase activity. Apixaban has no direct effect on platelet aggregation, but indirectly inhibits platelet aggregation induced by thrombin. By inhibiting FXa, apixaban…
Indications (13)
Clinical Trials (5)
REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults
Treatment With Apixaban Versus Warfarin in Patients With Left Ventricular Thrombus After Acute Myocardial Infarction
The Safety and Effectiveness of Warfarin Vs Apixaban in Patients with NVAF/ VTE and ESKD on Dialysis
A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation
A Study to Learn How Well the Study Treatment Asundexian Works and How Safe it is Compared to Apixaban to Prevent Stroke or Systemic Embolism in People With Irregular and Often Rapid Heartbeat (Atrial Fibrillation), and at Risk for Stroke
Loss of Exclusivity
Patent Records (4)
| Patent # | Expiry | Type | Use Code |
|---|---|---|---|
| 6967208 | Nov 21, 2026 | SubstanceProduct | U-4180 |
| 6967208*PED | May 21, 2027 | — | |
| 11896586 | Nov 22, 2040 | Product | U-4180 |
| 11896586*PED | May 22, 2041 | — |